The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
C. M. Rudin
Consultant or Advisory Role - Genentech; Novartis; OSI Pharmaceuticals; Syndax
A. Jimeno
No relevant relationships to disclose
W. H. Miller
No relevant relationships to disclose
B. J. Eigl
No relevant relationships to disclose
S. N. Gettinger
No relevant relationships to disclose
A. L. S. Chang
No relevant relationships to disclose
K. Faia
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
J. Sweeney
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
G. Loewen
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
R. W. Ross
Employment or Leadership Position - Infinity
Stock Ownership - Infinity
G. J. Weiss
Research Funding - Genentech; Lilly